Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zongertinib drug-drug interaction study with midazolam, omeprazole, and repaglinide
NCT06494761Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2024
- Primary completion
- Oct 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zongertinib, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Repaglinide in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 Extrapolated to Infinity and 4 more. Started Jul 2024; status: completed.
02
Drugs
zongertinib
Beyond the preview
Go deeper on NCT06494761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494761.